Results 91 to 100 of about 902 (167)
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder +13 more
wiley +1 more source
Linagliptin: from bench to bedside
Drug Design, Development and Therapy, 2014 John DoupisIatriko Palaiou Falirou Medical Center, Division of Diabetes, Athens, GreecePurpose: The nature of biomedical research affords a broad range of investigational topics at the preclinical stage, not all of which may be explored in subsequent ...
Doupis J
doaj
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To identify low‐ and high‐risk intervals for major adverse cardiovascular events (MACE) and all‐cause mortality according to lipid ratios in adults with Type 2 diabetes mellitus (T2DM), stratified by sex. Materials and Methods We used primary care electronic health records from the Spanish National Health Service including 303 199 adults ...
Enrique Carretero‐Anibarro +5 more
wiley +1 more source
Терапевтический архив, 2013 AIM: To study the impact of intensified therapy with the dipeptidyl peptidase-4 (DPP-4) inhibitor vilagliptin or sulfonylurea (SU) on the control of glycemia, weight, and quantitative body composition in patients with type 2 diabetes mellitus (DM-2) who ...
M V Shestakova +6 more
doaj
Diabetes, Metabolic Syndrome and Obesity, 2013 David ScottClinical Research Development Associates, Rosedale, NY, USAAbstract: Diabetes is the leading cause of chronic kidney disease, and the prevalence of both diseases is rising worldwide.
Scott D
doaj
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status. Materials and Methods This cross‐sectional study included 178 participants randomly selected in Sergipe, Brazil.
Liliane Viana Pires +10 more
wiley +1 more source